Neurocrine Biosciences (NBIX) Enterprise Value (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Enterprise Value for 17 consecutive years, with $16.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 45.92% year-over-year to $16.7 billion; the trailing twelve-month figure through Jun 2026 stood at $16.7 billion (up 45.92% YoY), and the FY2025 full-year result was $12.7 billion, up 1.8% from the prior year.
• Enterprise Value rose to $16.7 billion in Q2 2026 per NBIX's latest filing, from $11.9 billion in the prior quarter.
• Across five years, Enterprise Value topped out at $16.7 billion in Q2 2026 and bottomed at $8.2 billion in Q2 2023.
• Historically, Enterprise Value has averaged $11.1 billion across 5 years, with a median of $11.0 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 56.22% in 2024, then fell 20.99% in 2025.
• Over 5 years, Enterprise Value stood at $10.5 billion in 2022, then grew by 13.64% to $12.0 billion in 2023, then increased by 4.4% to $12.5 billion in 2024, then climbed by 1.8% to $12.7 billion in 2025, then soared by 31.59% to $16.7 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $16.7 billion, $11.9 billion, and $12.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.